Nautilus Biotechnology Inc (NAUT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,619 | N/A | N/A | N/A | N/A |
| Depreciation Amortization | 2,628 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 123 | N/A | N/A | N/A | N/A |
| Other Working Capital | -1,387 | N/A | N/A | N/A | N/A |
| Other Operating Activity | 259 | 0 | 0 | 0 | 0 |
| Operating Cash Flow | $-13,996 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -921 | N/A | N/A | N/A | N/A |
| Purchase Of Investment | -68,359 | N/A | N/A | N/A | N/A |
| Sale Of Investment | 44,001 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-25,279 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 42 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 75,857 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $75,899 | $N/A | $N/A | $N/A | $N/A |
| Beginning Cash Position | 595 | N/A | N/A | N/A | N/A |
| End Cash Position | 37,219 | N/A | N/A | N/A | N/A |
| Net Cash Flow | $36,624 | $N/A | $N/A | $N/A | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,996 | N/A | N/A | N/A | N/A |
| Capital Expenditure | -921 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -14,917 | 0 | 0 | 0 | 0 |